139 related articles for article (PubMed ID: 32608232)
1. Application of Native Ion Exchange Mass Spectrometry to Intact and Subunit Analysis of Site-Specific Antibody-Drug Conjugates Produced by AJICAP First Generation Technology.
Matsuda Y; Kliman M; Mendelsohn BA
J Am Soc Mass Spectrom; 2020 Jul; ():. PubMed ID: 32608232
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Analytical Methods for Antibody-Drug Conjugates Produced by Chemical Site-Specific Conjugation: First-Generation AJICAP.
Matsuda Y; Robles V; Malinao MC; Song J; Mendelsohn BA
Anal Chem; 2019 Oct; 91(20):12724-12732. PubMed ID: 31478640
[TBL] [Abstract][Full Text] [Related]
3. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T
Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528
[TBL] [Abstract][Full Text] [Related]
4. Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using a recombinant FcγIIIa receptor-ligand affinity column.
Matsuda Y; Chakrabarti A; Takahashi K; Yamada K; Nakata K; Okuzumi T; Mendelsohn BA
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jul; 1177():122753. PubMed ID: 34098178
[TBL] [Abstract][Full Text] [Related]
5. Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.
Matsuda Y; Malinao MC; Robles V; Song J; Yamada K; Mendelsohn BA
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1140():121981. PubMed ID: 32036254
[TBL] [Abstract][Full Text] [Related]
6. AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production.
Fujii T; Matsuda Y; Seki T; Shikida N; Iwai Y; Ooba Y; Takahashi K; Isokawa M; Kawaguchi S; Hatada N; Watanabe T; Takasugi R; Nakayama A; Shimbo K; Mendelsohn BA; Okuzumi T; Yamada K
Bioconjug Chem; 2023 Mar; 34(4):728-38. PubMed ID: 36894324
[TBL] [Abstract][Full Text] [Related]
7. Good Manufacturing Practice Strategy for Antibody-Drug Conjugate Synthesis Using Site-Specific Chemical Conjugation: First-Generation AJICAP.
Matsuda Y; Clancy C; Tawfiq Z; Robles V; Mendelsohn BA
ACS Omega; 2019 Dec; 4(24):20564-20570. PubMed ID: 31858041
[TBL] [Abstract][Full Text] [Related]
8. Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.
Friese OV; Smith JN; Brown PW; Rouse JC
MAbs; 2018 Apr; 10(3):335-345. PubMed ID: 29393747
[TBL] [Abstract][Full Text] [Related]
9. Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates.
Botzanowski T; Erb S; Hernandez-Alba O; Ehkirch A; Colas O; Wagner-Rousset E; Rabuka D; Beck A; Drake PM; Cianférani S
MAbs; 2017 Jul; 9(5):801-811. PubMed ID: 28406343
[TBL] [Abstract][Full Text] [Related]
10. State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis.
Deslignière E; Ehkirch A; Duivelshof BL; Toftevall H; Sjögren J; Guillarme D; D'Atri V; Beck A; Hernandez-Alba O; Cianférani S
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073805
[TBL] [Abstract][Full Text] [Related]
11. AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Selective Antibody-Drug Conjugate Synthesis.
Matsuda Y; Shikida N; Hatada N; Yamada K; Seki T; Nakahara Y; Endo Y; Shimbo K; Takahashi K; Nakayama A; Mendelsohn BA; Fujii T; Okuzumi T; Hirasawa S
Org Lett; 2024 Apr; ():. PubMed ID: 38639400
[TBL] [Abstract][Full Text] [Related]
12. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
13. Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment.
Debaene F; Boeuf A; Wagner-Rousset E; Colas O; Ayoub D; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
Anal Chem; 2014 Nov; 86(21):10674-83. PubMed ID: 25270580
[TBL] [Abstract][Full Text] [Related]
14. Impact of linker-drug on ion exchange chromatography separation of antibody-drug conjugates.
Zhang Z; Zhou S; Han L; Zhang Q; Pritts WA
MAbs; 2019; 11(6):1113-1121. PubMed ID: 31238787
[TBL] [Abstract][Full Text] [Related]
15. Biological Evaluation of Maytansinoid-Based Site-Specific Antibody-Drug Conjugate Produced by Fully Chemical Conjugation Approach: AJICAP®.
Seki T; Yamada K; Ooba Y; Fujii T; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Matsuda Y; Okuzumi T
Front Biosci (Landmark Ed); 2022 Aug; 27(8):234. PubMed ID: 36042175
[TBL] [Abstract][Full Text] [Related]
16. High-Throughput Multi-attribute Analysis of Antibody-Drug Conjugates Enabled by Trapped Ion Mobility Spectrometry and Top-Down Mass Spectrometry.
Larson EJ; Roberts DS; Melby JA; Buck KM; Zhu Y; Zhou S; Han L; Zhang Q; Ge Y
Anal Chem; 2021 Jul; 93(29):10013-10021. PubMed ID: 34258999
[TBL] [Abstract][Full Text] [Related]
17. Site-Specific Quantitation of Drug Conjugations on Antibody-Drug Conjugates (ADCs) Using a Protease-Assisted Drug Deconjugation and Linker-like Labeling (PADDLL) Method.
Yang X; Seol H; Lin W; Xu X; Shen B; Qiu H; Li N
Anal Chem; 2021 Jul; 93(27):9549-9558. PubMed ID: 34196532
[TBL] [Abstract][Full Text] [Related]
18. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry.
Sang H; Lu G; Liu Y; Hu Q; Xing W; Cui D; Zhou F; Zhang J; Hao H; Wang G; Ye H
Anal Chim Acta; 2017 Feb; 955():67-78. PubMed ID: 28088282
[TBL] [Abstract][Full Text] [Related]
19. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.
Marcoux J; Champion T; Colas O; Wagner-Rousset E; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
Protein Sci; 2015 Aug; 24(8):1210-23. PubMed ID: 25694334
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Drug-Antibody Ratio Determination of Antibody-Drug Conjugates.
Matsuda Y; Mendelsohn BA
Chem Pharm Bull (Tokyo); 2021; 69(10):976-983. PubMed ID: 34602579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
